Prognostic factors and staging systems of multiple myeloma: A single centre study in China

Chinese Medical Journal

Volumn 120, Issue 19, 2007, Pages 1655-1658

  Tao, Zhong Fei ^a   Fu, Wei Jun ^a   Yuan, Zhen Gang ^a   Wang, Dong Xing ^a   Chen, Yu Bao ^a   Hou, Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Clinical staging system; Multiple myeloma; Prognosis; Survival analysis

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; THALIDOMIDE; VINCRISTINE;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BONE LESION; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHINA; CHINESE; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PLASMA CELL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTE; UNIVARIATE ANALYSIS;

EID: 35348994526     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200710010-00002     Document Type: Article

References (16)

1. Kyle RA. Why better prognostic factors for multiple myeloma are needed. Blood 1994; 83: 1713-1716.
2. Stewart AK. Prognostic staging in myeloma: in search of biology. Blood 2003; 102: 778-779.
3. Clerc D, Fermand JP, Mariette X. Treatment of multiple myeloma. Joint Bone Spine 2003; 70: 175-186.
4. Yun JP, Suh C, Lee E, Chang JW, Yang WS, Park JS, et al. Comparison of serum beta 2-microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma. J Korean Med Sci 2006; 21: 639-644.
5. Facon T, Avet-Loiseau H; Guillerm G, Moreau P, Genevieve F, Zandecki M. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
6. Zhang ZN, Shen T, eds. The standards of diagnoses and therapeutic effects for blood diseases. 2nd ed. Beijing: Science Publication; 1998: 373-380.
7. Bushinsky DA, Monk RD. Electrolyte quintet: Calcium. Lancet 1998; 352: 306-311.
8. Blade J, San Miguel JF, Fontanillas M, Esteve J, Maldonado J, Alcala A, et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J 2001; 2: 272-278.
9. Turesson I, Abildgaard N, Ahlgren T, Dahl I, Holmberg E, Hjorth M, et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 1999; 106: 1005-1012.
10. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
11. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733-737.
12. Kuliszkiewicz-Janus M, Zimny A, Sokolska V, Saşiadek M, Kuliczkowski K. Immunoglobulin D myeloma - problems with diagnosing and staging (own experience and literature review). Leuk Lymphoma 2005; 46: 1029-1037.
13. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ. Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003; 122: 441-450.
14. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, et al. Targeting beta2- microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 2006; 10: 295-307.
15. Gao XJ, Lu ZX, Sun BT, Sun YX, Dai EY, Zhang XM. Multivariate prognostic analysis multiple myeloma a report of 187 cases. Chin J Hemotol (Chin) 2006; 27: 269-270.
16. Tichy M, Maisnar V, Palicka V, Friedecky B, Vavrova J, Novotna H, et al. International Staging System required standardization of biochemical laboratory testing in multiple myeloma. Neoplasma 2006; 53: 492-494.